

## Loading WHODrug Type C Format In TMS 4.5. Decision Points and Considerations



September 2004

Elaine Luscombe, i3 Data Services Sunil G. Singh, DBMS Consulting





Oracle Clinical Users' Group Meeting – September 2004
Acknowledgements



Thanks to Thanks to the OCUG and TMS Focus Group for this opportunity to present this topic

Thanks to Kim Renjdrup and Andy Alasso for their comments and feedback about possible implementations of WHODrug Type C in TMS

Thanks to Daniel von Sydow and Malin Nord at the WHO Uppsala Monitoring Center for their comments into this topic

Many thanks to the OCUG Presentation committee and Lori Venable for their patience with the completion of these presentations.

Oracle Clinical Users' Group Meeting – September 2004
Goals and Agenda



- Explain challenges to loading the WHO Drug Type C Format in TMS 4.5
- Identify the key decision points that must be addressed before loading
- Provide suggestions for possible loading and configuration options
- Provide suggestions on possible future enhancements and changes both to the WHODrug Type C format and TMS

Oracle Clinical Users' Group Meeting – September 2004
Brief TMS Overview



- TMS (Thesaurus Management System) is normally integrated with Oracle Clinical as well as other applications.
- During the Batch Validation process, the Verbatim Terms are compared to the dictionary data. The Level of the dictionary for which the Verbatim Term is compared is known as the Classification Level.
- If an exact match is found, then this matched term, and other associated data in the dictionary, is returned to Oracle Clinical

Oracle Clinical Users' Group Meeting – September 2004
Brief TMS Overview



TMS defines an exact match as :

Equivalent regardless of the case of the terms

and

 Equivalent regardless of the number of spaces between words of a multiple word term.



Oracle Clinical Users' Group Meeting – September 2004
Brief TMS Overview



- The process of resolving Verbatim Terms (VT) which do not exactly match some term in a medical dictionary is commonly called "coding." In TMS terminology, this is called **Omission Management.**
- When a VT is assigned to a dictionary term, the term and its auxiliary data, also called Level Details, is returned to Oracle Clinical in the next Batch Validation.
- Other parts of the medical dictionary, known as Derivable Levels, can be returned to Oracle Clinical at the same time.

Oracle Clinical Users' Group Meeting – September 2004 **TMS Limitations** 




- TMS must have unique terms in the Classification Level of a dictionary.
- TMS can only return dictionary data back to Oracle Clinical if the data exists in a single derivable path. This means that for every term in the Classification Level of a Dictionary, TMS must have a single default term from any level higher than the classification level in order to return that data to Oracle Clinical.

Oracle Clinical Users' Group Meeting – September 2004 Overview of WHODrug



- The WHODrug dictionaries are published by the Uppsala Monitoring Centre (UMC) on behalf of the World Health Organization (WHO).
- The WHODrug dictionary represents a collection of all manufactured drugs that have been reported to them.
- The WHODrug dictionary has had four major formats since 1968, with the current formats of Type B2 and Type C.



Oracle Clinical Users' Group Meeting – September 2004 Overview of WHODrug



The WHODrug dictionary contains many levels including :

- Drug Names
- Anatomical Therapeutic Classifications (ATCs)
- Ingredients
- Source Codes
- Manufacturers

There are about 1200+ ATCs, there are currently more than 60,000 actual unique Drugs in the Type C format.

#### Oracle Clinical Users' Group Meeting – September 2004 Differences in the WHODrug Type C Affecting TMS



- The Drug names themselves are **not** unique in Type C.
- ATC codes are now associated to every Drug Name in Type C
- A Pharmaceutical Product level, which contains the Pharmaceutical Form (PF), was introduced in Type C
- All ingredients and their amounts were introduced in Type C
- The Medicinal Product ID (MP ID), which represents 7 drug attributes, now uniquely identifies a drug (Drug Name, Name Specifier, Country, Manufacturer, All Ingredients w/ Strengths and Units, Pharmaceutical Form Drug Code (DrgRecNum+Seq1+Seq2))



DBMS Consulting, Inc. © 2004 Presented by: Sunil G. Singh and Elaine S. Luscombe



- Since the drug name is not unique in Type C, the drug name alone can not be loaded as the Classification level in TMS. Therefore, the drug names must be made unique somehow.
- In making drug names unique in Type C, the TMS built-in automatic matching would potentially be diminished. Some considerations have to be made for preserving TMS auto encoder efficiency.

Oracle Clinical Users' Group Meeting – September 2004



Option 1: Use the Medicinal Product ID itself to make the Drug Names unique in the classification level

Option 2: Use the logical expansion of the Medicinal Product ID to make the Drug Names unique in the classification level and possibly populate a VTA Level with Drug Names only

- Drug Name
- Name Specifier
- Country
- Manufacturer
- All concatenated Ingredients with their Strengths and Units,
- Pharmaceutical Form
- Drug Code (DrgRecNum+Seq1+Seq2)

Oracle Clinical Users' Group Meeting – September 2004
Choices (cont.)



Option 3: Add an additional level to store the Drug Names only as part of a Classification Group in the TMS WHODrug structure



Oracle Clinical Users' Group Meeting – September 2004 Option 1 : Medicinal Product ID at Classification Level

## Advantages

Easy to load

### Disadvantages


- Auto encoding would not be possible
- Coders would not have information needed to select correct VTA

Some have suggested adding the MP\_ID to <u>only</u> non-unique drug terms. This still leaves many terms (10,000+) which will not auto encode.



Oracle Clinical Users' Group Meeting – September 2004 How it Looks to the Coder





### DrugName MP\_ID



#### Oracle Clinical Users' Group Meeting – September 2004 What it Really Means !



🙀 Browse Repository Data (INGE	NIX_WHODD_200	13Q4_DOM) 🗧	***************		
	butto butto holy	⊂ All ⊂ D: ● Current			
-Anatomical Therapeutic Classifica	Term		Relation	Level	
	T AMPICILLIN SODI	JM NONE N/A	Strong	INGWHO03	IQ4-PT
<u> </u>					
orgenix_WHODrug_03Q4					
-Preferred Term					
<del>⊝                                    </del>					
	Query Standard	-	,		
⊖-⊖⊷⊙Ingredients	Unique Drug 🔶			Level	Medicina
⊖-:⊡Substances	T AMPICILLIN BENZ	ESP		UNIQUEDF	275
LiSource	AMPICILLIN BIOTI	KA CZE		UNIQUEDF	247
LiSource					
				_	
				_	
					,
	Polation	Town		Loug	
	Relation	AMPICILLIN SODI	II IM 20 047		
	<b>_T</b> Strong	AMPICILLIN SODI	011/1 30 247	INGWH003	G4-ING

#### MP\_ID 247 is Ampicillin Sodium



DBMS Consulting, Inc. © 2004 Presented by: Sunil G. Singh and Elaine S. Luscombe

#### Oracle Clinical Users' Group Meeting – September 2004 What it Really Means !



Browse Repository Data (INGENI)	(_WHODD_200	3Q4_DOM) 200023					
⊖-Dictionaries	Data Currency	OAll ODate □					
- Singenix_WHOATC_03Q4	Term	Current	Relation	Level		Code	PL?
⊖-Anatomical Therapeutic Classifica	C AMPICILLIN TRIH	YDRATE NONE N/A	Strong	INGWH0030	Q4-PT	251	
⊖←Unique Drug ATC							
└────────────────────────────────────						ļ	
⊖-Singenix_WHODrug_03Q4							
-Preferred Term							
· 우우 Unique Drug							
Verbatim Term	Query Standard	1 👻					
jeredients	Unique Drug 🔶			Level	Medicina	iproc	Sequence_k
	AMPICILLIN BENZ	Z ESP		UNIQUEDF	275		00000503028
Li)Source	T AMPICILLIN BIOT	IKA CZE		UNIQUEDF	247		00000502023
i i⊷-Source							
	1						
	Relation	Term		Level		Code	RGI
	T Strong	AMPICILLIN TRIHYDRATE:			Q4-ING	275	
	T Strong	CATALOGO DE ESPECIAL		·		_	
		-1	/ /				

#### MP\_ID 275 is Ampicillin Trihydrate.

#### Note the different Drug Codes



DBMS Consulting, Inc. © 2004 Presented by: Sunil G. Singh and Elaine S. Luscombe

Oracle Clinical Users' Group Meeting – September 2004

# Option 2 : Use the Logical Expansion of the MP ID



#### Advantages

 Information is available for coders to select appropriate VTA

#### Disadvantages

- Nothing auto encodes
- Load script is more complicated and takes longer
- Field length may require >CHAR 300

## The Logical Expansion of the MP ID



😨 Browse Repository Data (INGE	NIX_WHODD_2003Q4_DOM) 🕬		*************	**********		
-Dictionaries	Data Currency					
Ingenix_WHOATC_03Q4 Ingenix_WHOATC_03Q4 Ingenix_Unique Drug ATC Ingenix_WHODrug_03Q4 Ingenix_WHODrug_03Q4 Preferred Term Ingenix_Verbatim Term	Current Term     ACETYLSALICYLIC ACID NONE N/A	Relation Strong	Level INGWH003	Code Q4-PT 1066		DPL? RGIb
	Query Standard					-
(⊐-:⊷ilngredients	Unique Drug 🗢			Medicinalproc		
(⊃-;…;Substances	ASPIRIN 100 TABLETTEN BAYER AG C		UNIQUEDF		00002701004	Company
LiSource	T ASPIRIN 500 INSTANT-TABLETTEN BA	YER AG CHE			00002701004	Company
- Source	T ASPIRIN BAYER AG CHE				00002701004	Company
	T ASPIRIN BAYER DEU		UNIQUEDF		00002701004	Company
	I ASPIRIN BUFFERED LANNETT USA		UNIQUEDF	58511	00002701004	Company
	T ASPIRIN CARDIO 100 FILMTABLETTEN	BAYER AG CHE	UNIQUEDF	58330	00002701004	Company
	T ASPIRIN CARDIO 300 FILMTABLETTEN	BAYER AG CHE	UNIQUEDF	58331	00002701004	ompany
	ASPIRIN CARDIO BAYER FIN		UNIQUEDF	1248	00002701190	Company

#### Note the Aspirin Cardio includes the strength and form

Note the Drug Codes are the same

DBMS Consulting, Inc. © 2004

Oracle Clinical Users' Group Meeting – September 2004
So Nothing Auto Encodes ? Ever ?



 Answer - Load Verbatim Term Assignments (VTAs)

 This also allows coders to use the filter buttons in TMS Omission Management to choose the VTA Level and only code on the Drug Names if desired

Problem - Over 10,000 drug names are not unique.

Do you have to manually code all 10,000+?

Yes and No !

Oracle Clinical Users' Group Meeting – September 2004 Yes - Manually Code All Duplicate Drug Names



#### Advantages

- Control of the codes you can select certain drugs from specific countries, or manufacturers, or ingredients, etc.
- You could reload same VTAs, once they are selected to new versions of the dictionary.



Oracle Clinical Users' Group Meeting – September 2004 Yes - Manually Code All Duplicate Drug Names



Disadvantages

- As each version is released, you will need to repeat this exercise.
- How long will it take your team to code 10,000+ terms?
- Some of these terms you will never see in a study, but you will spend a lot of time on them initially.



Oracle Clinical Users' Group Meeting – September 2004 No - Don't do it Manually



- Load only the Unique Drug Names as verbatim terms.
- Code the others as they are encountered as verbatim terms.

#### **Advantages**

- Over 40,000 will be able to have VTAs loaded
- You only spend time on those you need

Oracle Clinical Users' Group Meeting – September 2004 No - Don't do it Manually



#### Disadvantages

- You may give up consistency in decision making if this is done over time
- Many of the most common drugs encountered are in this group
- You need to repeat this with each new version of the dictionary

Oracle Clinical Users' Group Meeting – September 2004 Alternative "No" - do it Systematically



#### Advantages

- Same script can be used for each new version of the dictionary
- Logic can be applied that is consistent across all term choices
- The script will run faster than your team can do the work!



- How do you decide which drugs should have VTAs?
- We feel that all the drugs having the same DrgRecNum and Seq1 and can have a VTA selected.
- The same DrgRecNum and Seq 1 mean the drug is the same drug with the same Preferred term and the same ingredients.
- Further, WHODrug will continue to support the DrgRecNum and Seq numbers (see the document titled <u>The New C Format</u>: New Features that accompanies each version of the dictionary).

**SS2** (can we reference a specific document from WHO-UMC here?) Sunil Singh, 7/20/2004 Oracle Clinical Users' Group Meeting – September 2004 Alternative "No" - do it Systematically

i3 data services

Disadvantages

- Decisions still need to be made on the logic to be used
- Some terms will not have VTAs because the same drug name by different countries/manufacturers are really different drugs
- TMS loading Script development is complex and will take some time to run!
- This does not account for PF or strength.

Oracle Clinical Users' Group Meeting – September 2004

Why not Assign Global VTAs to Drug Names with Multiple Drug Recnrs?



In WHODrug Type, 4th Quarter 2003, there were about 775 cases where there were Drug Names with multiple Drug Record numbers, and therefore potentially different ingredients, Preferred Names, and ATCs.

There are many reasons why this has happened :



Oracle Clinical Users' Group Meeting – September 2004 Reasons for Multiple Record Numbers



- A strategic decision by a manufacturer to change the active ingredients to improve the product over time, but keep the same Drug Name due to market share and brand recognition
- The lack of availability of some active ingredients in some countries or geographies, including cases where the raw materials are not available or are banned by a country for human use or import



- The purchase or acquisition of one company or brand by another combined with a strategic decision to keep the same brand recognition and market share purposes, but to also change or improve the drug which might change the active ingredients
- The lack of enforcement of intellectual property rights or patents in some countries, where the same Drug Name is used illegally and manufactured with completely different ingredients. WHO-UMC is still obligated to report the creation and use of these drugs.

Oracle Clinical Users' Group Meeting – September 2004

## Example of Same Drug Name in Different Countries



## **Benadryl** in Italy

॑ <del>_ᢞ</del> < <mark>Unique Drug</mark>							r
 ⊝–;⊷⊙Ingredients							
1							
(⊖-;…;Substances				 ( <b>∢</b>   ⇒	_		·
LiSource	Query Standar	rd 🚽			2		
LiSource	Unique Drug 🕯	•		Level		Medicinalproc	Sequence_ke
	T BENADRYL WA	ARNER LAMBERT CONSUMER HEAI	LTH IRL	UNIQ	UEDF	52370	00647601002
	T BENADRYL WA	ARNER LAMBERT CONSUMER HEAT	LTH USA	UNIQ	UEDF	51457	00000402049
	T BENADRYL WA	ARNER LAMBERT DNK		UNIQ	UEDF	52616	00945501004
	T BENADRYL WA	ARNER LAMBERT ESP		UNIQ	UEDF	51459	00000402051
	T BENADRYL WA	ARNER LAMBERT GBR		UNIQ	UEDF	52615	00945501003
				UNIQ	UEDF	51462	00000402054
	BENADRYL WA	ARNER LAMBERT ITA				52393	00673901009
	T DENADRYL W/	PHER LAMBERT THA				51458	00000402050
				<u>a</u> .	_	)	
		_					_
	Relation					opr? Alt Code	Туре
	_T Strong	SODIUM CITRATE 38 84982					Dictionary *
	_T Strong	MENTHOL 38 84983					Dictionary *
	T Strong	DIPHENHYDRAMINE HYDROCH	ILORIDE 38 84984	_ 🗹			Dictionary 1
	T Strong	AMMONIUM CHLORIDE 38 849	85				Dictionary 1
	T Strong	MARTINDALE - THE COMPLETE	E DRUG REFERENC				Dictionary 1



Oracle Clinical Users' Group Meeting – September 2004

## Example of Same Drug Name in Different Countries



### Benadryl in the United Kingdom

() 가운 <mark>Unique Drug</mark>		
⊖–∺⊷⊚Ingredients		
↓		
Li∋Source	Query Standard 👻	
LiSource	Unique Drug 🔶	Level Medicinalproc Sequence_k
	T BENADRYL WARNER LAMBERT CONSUMER HEALTH IRL	UNIQUEDF 52370 00647601002
	T BENADRYL WARNER LAMBERT CONSUMER HEALTH USA	UNIQUEDF 51457 00000402049
	T BENADRYL WARNER LAMBERT DNK	UNIQUEDF 52616 00945501004
	T DENADRY'L WARNER LAMDERT ESP	UNIQUEDF 51459 00000402051
	BENADRYL WARNER LAMBERT GBR	UNIQUEDF 52615 00945501003
	T BENADRYL WARNER LAMBERT HKC	UNIQUEDF 51462 00000402054
	T BENADRYL WARNER LAMBERT ITA	UNIQUEDF 52393 00673901009
	T BENADRYL WARNER LAMBERT THA	UNIQUEDF 51458 00000402050
	Relation Term	RGlb? Appr? Alt Code Type
	T Strong ACRIVASTINE 38 85279	Dictionary
	T Strong MARTINDALE - THE COMPLETE DRUG R	

DBMS Consulting, Inc. © 2004

Oracle Clinical Users' Group Meeting – September 2004
Changes in the Drug



#### **Robitussin AC**

-Preferred Term				1				
⇔ <del>P</del> < <mark>Unique Drug</mark>							;	
<u>_v</u> t∈Verbatim Term								
Ģ–∺⊷∃ngredients								
⊖–;…;Substances								
LiSource	Query Stand	ard 🚽	,			,		
LiSource	Unique Drug	•		Level	Medicina	lproc Seque	nce_ke	SubType
	T ROBITUSSIN A	A-C /OLD FORM/ ROBINS A.H. COM	PANY, INCORPORA	UNIQUEDF	11947	000742	01001	Company
Entered in 2002		AC ROBINS A.H. COMPANY, INCOR	PORATED USA COL		35354	006933	01008	Company
	T ROBITUSSIN A	AC WHITEHALL-ROBINS INC. CAN C	ODEINE PHOSPHAT	UNIQUEDF	11948	000742	01002	Company
				·				
								<u> </u>
	Relation	Term		Level		Code	RGlb	? Appr? A
	T Strong	CODEINE PHOSPHATE 38 519	100	INGWH003	Q4-ING	51900		
	T Strong	GUAIFENESIN 38 51 901		INGWH003	Q4-ING	51901		
	T Strong	AMERICAN DRUG INDEX				010		

DBMS Consulting, Inc. © 2004

Oracle Clinical Users' Group Meeting – September 2004
Changes in the Drug



## Robitussin AC

⊖-Dictionaries	Query Standa	ard 🗸				
∲- <b>%</b> Ingenix_WHOATC_03Q4	Unique Brug	÷	Level	Medicinalpro	Sequence_I	<b>ke</b> g
- Singenix_WHODrug_03Q4	ROBITUSSIN A	-C /OLD FORM/ ROBINS A.H. COMPANY, INCORPO		11947	00074201001	1
-Preferred Term		C ROBINS A.H. COMPANY, INCORPORATED USA (	COE UNIQUEDR	35354	00693301008	8 [
<mark>승 운</mark> 숙 <mark>Unique Drug</mark>	T ROBITUSSIN A	CWHITEHALL-ROBINS INC. CAN CODEINE PHOSP	HAT UNIQUED	11948	00074201002	2
 ⊝–;⊶⊙Ingredients						
	Relation	Term	Level	Code	e Ri	Glb?
Entered in 1985	T Strong	CODEINE PHOSPHATE 38 13807	INGWHO0:	3Q4-ING 138	07 🔽	2
	T Strong	GUAIFENESIN 38 1 3808	INGWH00	3Q4-ING 138	08 🔽	2
	_T Strong	PHENIRAMINE MALEATE 38 13809	INGWHO0:	3Q4-ING 138	09 🔽	2
	_T Strong	AMERICAN DRUG INDEX	INGWHO0:	3Q4-SRCE 010		7
	_T Strong	ROBITUSSIN A-C	INGWHO0:	3Q4-VT		2





Oracle Clinical Users' Group Meeting – September 2004

## Default Algorithm for Preserving TMS Auto Coding WHODrug Type C



- 1. Where only one Medicinal Product ID exists for a specific Drug Name, then make this Drug Name a Verbatim Term.
- 2. Where multiple Medicinal Product IDs exist for a specific Drug Name, but only one Medicinal Product ID has Seq2='001' (i.e., a unique Preferred Term), then make this Drug Name a Verbatim Term.
- 3. Where multiple Medicinal Product IDs exist for a specific Drug Name, and multiple Medicinal Product IDs have Seq2='001' but only one Medicinal Product ID has COUNTRY='UNS' (i.e., the Country code is Unspecified), then make this Drug Name a Verbatim Term.

Oracle Clinical Users' Group Meeting – September 2004

# Default Algorithm For Preserving TMS Auto Coding WHODrug Type C



4. Where multiple Medicinal Product IDs exist for a specific Drug Name, and multiple MP IDs have Seq2='001' and multiple MP\_IDs have COUNTRY='UNS', then make the Drug Name of the lowest Medicinal Product ID the Verbatim Term

Note: If you use the Maximum MP\_ID your VTAs will be altered in newer versions of the dictionary as MP\_IDs are added.





Oracle Clinical Users' Group Meeting – September 2004

# Default Algorithm for Preserving TMS Auto Coding WHODrug Type C



- 5. Where multiple Medicinal Product IDs exist for a specific Drug Name, and no Medicinal Product ID has Seq2='001' but only one Medicinal Product ID has COUNTRY='UNS' (i.e., the Country code is Unspecified), then make this Drug Name the Verbatim Term.
- 6. Where multiple Medicinal Product IDs exist for a specific Drug Name, and no Medicinal Product ID has Seq2='001' and no Medicinal Product ID has COUNTRY='UNS', then make the Drug Name with the lowest Medicinal Product ID the Verbatim Term.





DBMS Consulting, Inc. © 2004 Presented by: Sunil G. Singh and Elaine S. Luscombe

#### Oracle Clinical Users' Group Meeting – September 2004

# View of TMS, Classification Level in WHODrug Type C



🙀 Browse Repository Data (INGE	NIX_WHODD_2003Q4_DOM) 3333	***************			2000-2000 <b>- 2</b> 0
-Dictionaries	Data Currency				
₽-S Ingenix_WHOATC_03Q4	Current     Term	Relation	Level	Code PL?	DPL? RGIb? Ap
- Singenix_WHODrug_03Q4	T ACETYLSALICYLIC ACID NONE N/A		INGWH003Q4-PT	1066	
-Preferred Term					
⇔ <mark>િ ⊬</mark> ← <mark>Unique Drug</mark>					
⊖-⊖-⊙Substances					
Li-Source	Query Standard				D
LjSource	Unique Drug 🔶		Level Medicin	alproc Sequence_ke	SubType
	T ACETYLSALICYLIC ACID BAYER DEU		UNIQUEDF 1250	00002701192	Company 🚽
	I ACETYLSALICYLIC ACID BRISTOL-MYER	RS SQUIBB DEU	UNIQUEDF 1253	00002701195	Company 🚽
	T ACETYLSALICYLIC ACID ENTERIC COAT	ED NOT SPECIFIED CAN	UNIQUEDF 1090	00002701025	Company 🚽
	T ACETYLSALICYLIC ACID GRAIN V GAVE	ERNMENT PHARMACEUTICA	UNIQUEDF 1194	00002701135	Company 🚽
	T ACETYLSALICYLIC ACID LAPHAL FRA		UNIQUEDF 1180	00002701120	Company 🚽
	T ACETYLSALICYLIC ACID MICHALLIK FRI	TZ OSK. GMBH DEU	UNIQUEDF 1252	00002701194	Company 🚽
	T ACETYLSALICYLIC ACID MONOT FRA		UNIQUEDF 1173	00002701112	Company 🚽
	ACETYLSALICYLIC ACID NONE N/A		UNIQUEDF 1066	00002701001	Company 🚽
	RelationTerm		RGIb?_Appr?_Alt C	ode Type	SubTy
	Strong ACETYLSALICYLIC A			Dictionary	Term 🚽 Comp
		NAL PHARMACOPOEIA - V		Dictionary	Term 👻 Comp:
	_T Strong ACETYLSALICYLIC A	CID		Verbatim 1	ferm 🚽 Accep

### Oracle Clinical Users' Group Meeting – September 2004 Derivable Level Details with Drug Name and Preferred Drug Name in WHODrug Type C



🙀 Define Dictionaries Level Relations Level Details Level 1 OV Enter Update Valida Manda ⊡-\\\ AHODrug Type C Level Detail able? able? tion? tory? Entry Length Data Type Label - Preferred Term 11 Sequence Key Dict Content Alt ... Char Preferred\_Term 80 Value 1 Char 1 <u>-₩∓</u>⊖Verbatim Term 80 Drug Name Value 2 Char 7 80 Product Type Value 3 Char  $\mathbf{V}$ 121 Unique ATC+ATC Value 4 . ⊖-∋…∈Substances Char 6 Medicinalprod id Dict Content Co... Number 🔻 Le: Source  $\square$ -÷--?Source Description Term for a UniqueDrug where Sequence2 = `001`



Oracle Clinical Users' Group Meeting – September 2004
Want One More Option ?



Option 3: Creating a new level in TMS between Classification level and VT.

During the OPA 5.0 Enhancement meeting from 11-12 May 2004, Oracle OPA Development has suggested creating an intermediate level within the TMS dictionary itself to preserve auto coding.



# Oracle Clinical Users' Group Meeting – September 2004 Option 3 : New Level in TMS



Consider the possibilities.....

- Load Classification level with Drugname\_MPID
  - This level is now unique and since your are not going to try to "code" anything to it, it does not need additional description
- For all drugs at the classification level, determine if there are multiple drug names and, for those, if they have the same or different DrgRecNum and SeqN 1
- If the Drug Name is unique, load it at the middle level intermediate



- If the Drug Name is not Unique, but all the DrgRecNum|SeqN1's are the same, verify that the PF, Strength and Ingredients are all the same and then choose one to DrugName\_MPID to represent the rest and load that at the middle intermediate level.
- You can use the logic presented earlier or some other similar, reproducible logic for selecting which one will represent all these drugs that are the same.
- This would be a stored relation in the TMS dictionary structure



- Additionally, some other extensions of this option might make it more useful:
  - Where an entry is made the Intermediate Middle Level, also make a corresponding entry to a VTA level (combining aspects of Option 2)
  - All other non-unique drug names including multiple cases of the same drug name with different DrgRecNums| Seq1 can be loaded to the new mid-level with Drugname\_PharmaceuticalForm\_Strength\_ Ingredients
  - This level will now give you the information your coders need to make decisions on the correct one to chose for coding.
  - A primary link could be considered between the Unique Drug classification level and the Intermediate Level.



DBMS Consulting, Inc. © 2004 Presented by: Sunil G. Singh and Elaine S. Luscombe

Oracle Clinical Users' Group Meeting – September 2004 Other Considerations of Option 3: Loading New Level



- Loading an additional dictionary level would require structural changes to the existing relations between the Unique Drug Names classification level and the intermediate Middle Level in order to change the default Drug Name/MP\_ID, that is, the default coding behavior. These changes would be made through Maintain Repository Data, which can lead to other data-related mistakes or exposures of bugs which can be very difficult to repair.
- Some thinking from a validation perspective might be that the structure and data of a vendor dictionary should never be modified. In this context, modification of VTAs is not the same as modification of the WHO-UMC's dictionary data or dictionary structure



## Oracle Clinical Users' Group Meeting – September 2004 Dictionary Updates and Reducing Data Scope



- One consideration is whether or not all of the Drug data should be loaded. Why not parse all of the Drug Names only and simple load these Drug Names?
  - Not Loading the MP\_ID or loss of the MP\_ID will make updating this dictionary very difficult. This is because the default TMS APIs for updating the dictionary, TMS\_LOAD\_DICTIONARY.MigrateRelations and TMS\_LOAD\_DICTIONARY.MigrateTerms expect a unique DICT\_CONTENT\_CODE in the dictionary which comes from the vendor which can be compared with queries against the vendor source data to determine what DICT\_CONTENT\_CODEs to insert/update/delete.
  - Additionally, during the dictionary load process, it is not required to specify a DICT\_CONTENT\_CODE nor is uniqueness enforced! But during update calls using the TMS\_LOAD\_DICTIONARY API, it is a de facto expectation.



# Oracle Clinical Users' Group Meeting – September 2004 Dictionary Updates and Reducing Data Scope (2)



- This means not having the MP\_ID for all of the WHODrug source data will make updating very difficult. Calls to TMS\_USER\_MT\_DICTIONARY for updating, inserting and deleting terms will have to be made on a separate basis, without the benefit of the TMS migration APIs.
- Additionally, if only part of the drug data is loaded (a reduction in the data scope), it may be possible to make a validation argument that the dictionary loaded in TMS was not actually a representation of the WHO-UMCs WHODrug dictionary, but a customized dictionary which is a proprietary to a single organization, which may introduce some additional validation requirements.

## Oracle Clinical Users' Group Meeting – September 2004 Some Suggested TMS Enhancements



- Not Requiring Classification Level to be Unique, but instead requiring the combination of the TERM\_UPPER along with LEVEL\_1 to be unique?
- Allowing configurable column lengths in TMS\_DICT\_CONTENTS for TERM and TERM\_UPPER, so that customers which require a longer Term field (such as Option 2) can extend their classification content past 300 Characters?
- Create a TMS codelist which is default enables which requires dictionaries to be loaded with DICT\_CONTENT\_CODEs which are not null and unique?

Oracle Clinical Users' Group Meeting – September 2004
Additional Discussions



- Consider the slide for Aspirin Should medications be coded to the level of detail available in the dictionary?
   If so, how will you accomplish this?
- 2. Could a procedure be built into OC/TMS that allows for merging specified fields together and have THAT be the VTA that is classified in TMS?
- 3. Do your CRFs include all the needed information?
- 4. Will the information be used?

Oracle Clinical Users' Group Meeting – September 2004
Questions / Contacts



Sunil G. Singh Director, DBMS Consulting e-mail: singh@clinicalserver.com Pager: +1 888 463 4751 Mobile: +1 860 983 5848

Elaine Luscombe

Manager, Data Services Support e-mail: <u>elaine.luscombe@i3data.com</u> Phone: +1 973 348 1288

Visit us at our respective booths in the Exhibit Hall



DBMS Consulting, Inc. © 2004 Presented by: Sunil G. Singh and Elaine S. Luscombe